{"DataElement":{"publicId":"4857994","version":"1","preferredName":"Transplant Conditioning Regimen Type","preferredDefinition":"The type of treatment regimen related to preparing a person for receipt of a transplant.","longName":"TRANSPTRTTYPE","context":"Alliance","contextVersion":"1","DataElementConcept":{"publicId":"2198273","version":"1","preferredName":"Transplant Conditioning Regimen","preferredDefinition":"A treatment plan to prepare a person for receipt of a transplant.","longName":"TSPL_COND_RGM","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"2206967","version":"1","preferredName":"Transplant Conditioning","preferredDefinition":"Healthy skin, bone, or other tissue taken from one part of the body and used to replace diseased or injured tissue removed from another part of the body.:Generally refers to relative simple learning situations in which a stimulus initially incapable of evoking a certain response acquires the ability to do so by repeated pairing with another stimulus that does elicit the response.","longName":"C12981:C41258","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Graft","conceptCode":"C12981","definition":"Tissue or organ transplanted from a donor to a recipient.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Conditioning","conceptCode":"C41258","definition":"Generally refers to relative simple learning situations in which a stimulus initially incapable of evoking a certain response acquires the ability to do so by repeated pairing with another stimulus that does elicit the response.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0429-1262-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177402","version":"1","preferredName":"Regimen","preferredDefinition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","longName":"Regimen","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Treatment Regimen","conceptCode":"C15697","definition":"A treatment plan that specifies the dosage, the schedule, and the duration of treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-527D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"EEFD9E97-FD88-0048-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2005-02-02","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"4857991","version":"1","preferredName":"Transplant Conditioning Regimen Type","preferredDefinition":"Something distinguishable as an identifiable class based on common qualities.","longName":"TRANSPTRTTYPE","context":"Alliance","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"BEAM","valueDescription":"BCNU (carmustine), Etoposide, Ara-C (cytarabine), Melphalan","ValueMeaning":{"publicId":"4857992","version":"1","preferredName":"BCNU (carmustine), Etoposide, Ara-C (cytarabine), Melphalan","longName":"4857992","preferredDefinition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04): A drug used to treat certain types of leukemia and prevent the spread of leukemia to the meninges (three thin layers of tissue that cover and protect the brain and spinal cord). It is also being studied in the treatment of other types of cancer. Cytarabine blocks tumor growth by stopping DNA synthesis. It is a type of antimetabolite.: A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Cytarabine","conceptCode":"C408","definition":"An antimetabolite analogue of cytidine with a modified sugar moiety (arabinose instead of ribose). Cytarabine is converted to the triphosphate form within the cell and then competes with cytidine for incorporation into DNA.  Because the arabinose sugar sterically hinders the rotation of the molecule within DNA, DNA replication ceases, specifically during the S phase of the cell cycle.  This agent also inhibits DNA polymerase, resulting in a decrease in DNA replication and repair. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Melphalan","conceptCode":"C633","definition":"A phenylalanine derivative of nitrogen mustard with antineoplastic activity. Melphalan alkylates DNA at the N7 position of guanine and induces DNA inter-strand cross-linkages, resulting in the inhibition of DNA and RNA synthesis and cytotoxicity against both dividing and non-dividing tumor cells.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1803CC5E-85FC-4409-E050-BB89AD4333F8","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1803CC5E-8615-4409-E050-BB89AD4333F8","beginDate":"2015-06-08","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"},{"value":"CBV","valueDescription":"Cytoxan (cyclophosphamide), BCNU (carmustine), VP-16 (etoposide)","ValueMeaning":{"publicId":"4857993","version":"1","preferredName":"Cytoxan (cyclophosphamide), BCNU (carmustine), VP-16 (etoposide)","longName":"4857993","preferredDefinition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.: An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04): A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclophosphamide","conceptCode":"C405","definition":"A synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Carmustine","conceptCode":"C349","definition":"An antineoplastic nitrosourea. Carmustine alkylates and cross-links DNA during all phases of the cell cycle, resulting in disruption of DNA function, cell cycle arrest, and apoptosis.  This agent also carbamoylates proteins, including DNA repair enzymes, resulting in an enhanced cytotoxic effect.  Carmustine is highly lipophilic and crosses the blood-brain barrier readily. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Etoposide","conceptCode":"C491","definition":"A semisynthetic derivative of podophyllotoxin, a substance extracted from the mandrake root Podophyllum peltatum.  Possessing potent antineoplastic properties, etoposide binds to and inhibits topoisomerase II and its function in ligating cleaved DNA molecules, resulting in the accumulation of single- or double-strand DNA breaks, the inhibition of DNA replication and transcription, and apoptotic cell death.  Etoposide acts primarily in the G2 and S phases of the cell cycle. (NCI04)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"1803CC5E-8623-4409-E050-BB89AD4333F8","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-06-08","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"1803CC5E-863C-4409-E050-BB89AD4333F8","beginDate":"2015-06-08","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-06-08","modifiedBy":"ONEDATA","dateModified":"2015-06-08","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2234813","version":"1","preferredName":"Type","preferredDefinition":"Type; a subdivision of a particular kind of thing.","longName":"C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F970CDF6-F90E-21D3-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-14","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-06-14","modifiedBy":"SBR","dateModified":"2005-09-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1803CC5E-85E3-4409-E050-BB89AD4333F8","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-06-08","modifiedBy":"ZIEGLERK","dateModified":"2015-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Type of transplant regimen pl","type":"Preferred Question Text","description":"Type of transplant regimen planned","url":null,"context":"Alliance"}],"origin":"Alliance Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1803CC5E-8647-4409-E050-BB89AD4333F8","latestVersionIndicator":"Yes","beginDate":"2015-06-08","endDate":null,"createdBy":"ZIEGLERK","dateCreated":"2015-06-08","modifiedBy":"ZIEGLERK","dateModified":"2015-07-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}